Navigation Links
Introgen and Clinical Collaborators to Report New Results with,Advanced-Stage Cancer Therapies at Upcoming Medical Meetings

s, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using tumor suppressors, cytokines and genes. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.

Statements in this release that are not strictly historical may be "forward-looking" statements, including those relating to Introgen's future success with its ADVEXIN, INGN 241, and INGN 007 clinical development programs. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgen's operations and business environment, including Introgen's stage of product development and the limited experience in the development of gene-based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen's product candidates, the ability to obtain the appropriate regulatory approvals, Introgen's patent protection and market acceptance, as well as other risks detailed from time to time in Introgen's filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.

Editor's Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen's Website at: www.introgen.com.

Contact

Introgen Therapeutics, Inc., Austin
C. Channing Burke, 512-708-9310, ext. 322
c.burke@introgen.com


'"/>




Page: 1 2 3

Related medicine technology :

1. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
2. Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241 in Patients With Advanced Solid Tumors
3. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
4. Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgens INGN 241
5. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
6. Genetic Analysis Systems Enter the Clinical Mainstream
7. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
8. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
9. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
10. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
11. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
Post Your Comments:
(Date:7/31/2014)... , July 31, 2014 genae, a ... industries, announced today the incorporation of genae UK in ... has one of the largest medical device markets in the ... it is projected to increase by a CAGR of 6.0% until ... equal to 9.5% of GDP. Despite recessionary pressures, market growth rates ...
(Date:7/31/2014)... 31, 2014 Astellas has appointed ... and employee communications in the Americas region. Knight ... senior vice president, chief communications officer. In this ... leading corporate brand initiatives and reputation management to ... South America . She will ...
(Date:7/31/2014)... -- The Galien Foundation today announced the 2014 nominees ... Awards. The Prix Galien Award is considered ... scientific and clinical research skills necessary to develop innovative ... highest number of nominees since the inception of the ... biomedical products across three categories – biotechnology, pharmaceutical, and ...
Breaking Medicine Technology:genae Opens Offices in London 2Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 2The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 3The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 4The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 5
... 5, 2011 SyncMedical LLC today announced ... – Brazilian National Health Surveillance Agency) has approved their ... in Brazil. SyncMedical,s Ethos Spine product line was developed ... treatment solutions to surgeons in the ever-growing, ever-changing field ...
... Jan. 5, 2011 Heska Corporation (Nasdaq: HSKA ... Conference hosted by Sidoti & Company, LLC on Monday, January ... 42nd Street (Park Avenue at Grand Central) in New York ... Eastern Time. (Logo:   http://photos.prnewswire.com/prnh/20000622/HESKALOGO ) ...
Cached Medicine Technology:SyncMedical Receives ANVISA Regulatory Approval to Offer Spine and Internal Medicine Products in Brazil 2
(Date:7/31/2014)... 2014 0-6 Pack Abs has finally been ... therapist expert Dr. James Vegher. Together they have launched ... relieve digestive issues, tone core muscles, improve posture, eliminate achy ... core exercises used to re-train the body in order to ... 0-6 Pack Abs review, Shane Michaels, a fitness ...
(Date:7/31/2014)... In today’s world, a good night’s sleep has ... sleep apnea (a medical problem where the airway collapses during ... of the rest they need to face their daily challenges. ... 20 million people in the United States alone have sleep ... and of those treated, many cannot tolerate their prescribed medical ...
(Date:7/31/2014)... Hook Your Ex, a system created by Steve Pratt, ... hungry for their partner, to the point of starvation, that they ... has been taught to hundreds of men and women across the ... Ex review , Shane Michaels agrees this simple trick is genius ... a second chance at getting back together with their ex. ...
(Date:7/31/2014)... 2014 Jeremiah’s Tavern ... wood to create a unique atmosphere and highlight ... features reclaimed barn siding on the ... mixed softwoods flowing throughout the interior as flooring. ... sister company New Energy Works Timberframers ...
(Date:7/31/2014)... US Hair Restoration Founder, Dr. Parsa Mohebi, has recently ... Mohebi Hair Restoration. Since first opening in 2008, US ... and around the world, who traveled to one of its ... patients achieved the full benefits of a variety of hair ... Dr. Mohebi. They have come to understand how his ...
Breaking Medicine News(10 mins):Health News:Zero To Six Pack Abs System Review Exposes Tyler Bramlett And Dr. James Veghers’ New Ab Training Program 2Health News:Zero To Six Pack Abs System Review Exposes Tyler Bramlett And Dr. James Veghers’ New Ab Training Program 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Hook Your Ex Review by Shane Michaels Exposes Steve Pratt And His New Method For Getting Back With The Ex 2Health News:Popular Tavern Restaurant Features Pioneer Millworks’ Reclaimed Wood in New Locations 2Health News:US Hair Restoration Becomes Parsa Mohebi Hair Restoration 2
... GAP, Pa., April 1, 2008 Core People ... Service Corporation,(CCSC) of Wexford, PA. CCSC provides options ... benefits for Pennsylvania chamber members through,its ChamberChoice portfolio., ... to offer a,broader level of employer services, including ...
... Awareness among Hispanic Community as Fewer ... Receiving Diagnosis and Support, CHICAGO, April 1, ... individuals living with autism, among the,vast array of services the national ... the last 20 years, Easter Seals has seen a dramatic increase ...
... rates to that from younger donors , , TUESDAY, April ... 75 should be allowed to donate corneas for transplant, says ... that tissue from donors aged 66 to 75 had the ... aged 12 to 65. , The research, coordinated by the ...
... the pharmaceutical industry currently underway will increase in the ... researcher at the National Institutes of Health (NIH) who ... development. , According to Christopher Austin, M.D., ... industry and academia welcome more cooperation in drug discovery ...
... CHICAGO, Ill. (April 1, 2008) Many patients ... percutaneous coronary intervention (PCI) are already taking 75mg ... Even so, an additional 600-mg reloading dose of ... risk of bleedingbut only in patients with acute ...
... 1, 2008 Senetek PLC (OTC,Bulletin Board: SNKTY), ... technologies that target the science of healthy aging, ... has secured financing in an,amount up to $28 ... of men,s health treatments, including Invicorp(R)., Plethora ...
Cached Medicine News:Health News:Core People Partners to Expand Services 2Health News:Easter Seals Notes April's Autism Awareness Month to Highlight Services Available to Families Living With Autism 2Health News:Easter Seals Notes April's Autism Awareness Month to Highlight Services Available to Families Living With Autism 3Health News:Study Finds Older Corneas Suitable for Transplantation 2Health News:Business of drug development on verge of great change 2Health News:Clopidogrel reloading worthwhile in acute coronary syndromes 2Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 2Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 3Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: